Vaxartﾒs oral COVID-19 vaccine candidate induced potent systemic and mucosal immune responses in preclinical studies
On Sept. 8, 2020, Vaxart announced pre-publication of a manuscript titled ﾓPreclinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection.ﾔ The manuscript described the pre-clinical development of a SARS-CoV-2 (COVID-19) vaccine based on Vaxartﾒs oral adenovirus platform.
Tags:
Source: Vaxart
Credit:
